Global IVD portfolio Burning Rock Biotech operates CLIA/CAP accredited laboratories in China and the United States with multiple IVD kits and CE-marked assays, presenting a strong foundation for expanding clinical trial services, companion diagnostics development, and regulatory-compliant assays to global pharma partners.

HRD and PARP opportunity Recent and ongoing HRD testing kit development and expansion plans, including collaboration with licensed HRD technologies and OncoScreen Plus, create a pathway to broaden PARP inhibitor treatment support in multiple international markets.

Pharma collaboration Existing partnerships for genomic data solutions, clinical trial support, and companion diagnostics development position Burning Rock to upsell integrated services to pharmaceutical companies seeking end-to-end precision oncology workflows.

Central lab shifts Despite a current decline in central lab revenue, strong performance in in-hospital and pharma research services suggests a strategic opportunity to re-balance offerings toward site-based testing, CRO-style services, and pandemic-resilient revenue streams.

Expansion potential Plans to leverage Myriad’s HRD technologies with proprietary platforms to launch next-generation HRD testing beyond China indicate a scalable international market entry, offering sales outreach to global oncology centers and payers seeking broader HRD-enabled treatment guidance.